D/E 0.01 — less debt than most Healthcare peers (≈25th pctile)
P/S14.4xC
P/S 14.4x — expensive vs Healthcare peers (≈90th pctile)
PEG0.81B+
PEG 0.81 — near fair value, classic Lynch benchmark (1.0)
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 66
Quality0.47
Growth0.91
Value0.67
Why this score
Diluting shareholders
Entry · Margin of safety
52-week rangeNear 52-week high
10% off the 12-month high
vs DCF fair value375% aboveest. fair value ~$23
What the price assumes: free cash flow compounding at ~58% a year for the next decade — vs the ~25% a year our model projects from current growth and analyst estimates.
Quality signals · context only
Gross profitability92% · Agross profit ÷ total assets (Novy-Marx)
ROIC0.7% · Creturn on invested capital — not score-weighted
Why now
Biotechnology · market cap $11.9b. 10% off the 52-week high of $122.21. Revenue growing +16%, comfortably above the S&P median. PEG 0.81 — paying under fair value for the growth rate. 4 sell-side analysts rate this a Buy with a mean 1-yr target of $135.25 (implying +23% upside).
Moat
FCF converts 194% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
P/S 14.4x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. ROE 8% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon
1-3 yr $135.25 (4-analyst consensus) — catalyst-driven; binary events dominate. 5 yr $236.55 — requires the platform / technology to reach commercial scale. 10 yr $422.77 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
CORT vs the Top Picks average
Pillar
CORT
Book avg
Diff
Quality
0.47
0.83
-0.35
Growth
0.91
0.91
in line
Value
0.67
0.75
-0.07
Averaged across the 30 names in today's Top Picks (mean score 81.8). A name can beat these averages and still be absent from the book — it also applies concentration limits.
Score history · CORT
Trend
+1.5 over 34 daily scores
From 64.5 (Jun 22) → 66.0 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Position sizing · CORT
$
%
%
Shares to buy
18
Position size
$1,987
4.0% of portfolio
Stop price
$82.78
25% below $110.38
$ at risk if stopped
$496.69
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Corcept Therapeutics Incorporated (CORT) is a Biotechnology company that scores 66 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are D/E (A-), Rev (B+) and PEG (B+). On valuation, CORT sits about 375% above our discounted-cash-flow fair value — the current price implies roughly 58% annual free-cash-flow growth over the next decade.
Is CORT a good stock to buy?
Bull Rankings scores CORT 66 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by D/E (A-), Rev (B+) and PEG (B+). A score is a quantitative screen of Corcept Therapeutics Incorporated's fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does CORT score 66 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). CORT earns its highest marks on D/E (A-), Rev (B+) and PEG (B+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is CORT overvalued or undervalued?
Based on $110.38, CORT sits about 375% above our discounted-cash-flow fair value — the current price implies roughly 58% annual free-cash-flow growth over the next decade. Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in CORT?
P/S 14.4x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. ROE 8% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.